crotamiton profile

ID Source	ID
PubMed CID	688020
CHEMBL ID	1200709
SCHEMBL ID	32934
MeSH ID	M0047173
PubMed CID	2883
CHEMBL ID	3183440
CHEBI ID	31439
MeSH ID	M0047173

Synonym
AB00513973-09
BRD-K57179821-001-05-5
crotamiton ,
2-butenamide, n-ethyl-n-(2-methylphenyl)-
ai3-17732
epa pesticide chemical code 055701
veteusan
eurasil
n-ethyl-n-(2-methylphenyl)-2-butenamide
einecs 207-596-3
eurax
caswell no. 431b
brn 3275497
crotonyl-n-ethyl-o-toluidine
crotamitone
crotalgin
crotamitonum [inn-latin]
o-crotonotoluidide, n-ethyl-
euraxil
inchi=1/c13h17no/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10h,5h2,1-3h3/b8-4
PRESTWICK2_000951
nsc-78382
nsc78382
BPBIO1_001038
BSPBIO_002722
BSPBIO_000942
MLS001424003
AB00513973
MLS000759489
smr000059145
n-ethyl-o-crotonotoluidide
483-63-6
D01381
crotamiton (jan/usp/inn)
eurax (tn)
n-ethyl-o-crotonotoluidide, 97%
NCGC00094571-02
NCGC00094571-01
NCGC00094571-03
SPECTRUM1505271
PRESTWICK3_000951
NCGC00094571-04
NCGC00094571-05
HMS2051E10
HMS2093O12
HMS2090A10
E0814
124236-29-9
n-crotonyl-n-ethyl-o-toluidine
trans-n-ethyl-n-(o-tolyl)-2-butenamide
MLS002695895
nsc-758951
CHEMBL1200709
MLS002222307
crotamitonum
(e)-n-ethyl-n-(2-methylphenyl)but-2-enamide
HMS1922P21
HMS1570P04
HMS2097P04
NCGC00254708-01
tox21_300804
A827519
(e)-n-ethyl-n-(o-tolyl)but-2-enamide
nsc758951
pharmakon1600-01505271
tox21_110446
HMS2234E16
CCG-39402
bestloid
3-12-00-01856 (beilstein handbook reference)
g 7857
crotamiton [usp:inn:ban:jan]
crotamitex
unii-d6s4o4xd0h
nsc 758951
(2e)-n-ethyl-n-(2-methylphenyl)but-2-enamide
S1711
AKOS015892746
BRD-K13240564-001-01-8
NC00107
SCHEMBL32934
NCGC00094571-08
tox21_110446_1
2EEH27851Y ,
crotamiton, (e)-
2-butenamide, n-ethyl-n-(2-methylphenyl)-, (e)-
trans-crotamiton
2-butenamide, n-ethyl-n-(2-methylphenyl)-, (2e)-
n-ethyl-n-(o-tolyl)but-2-enamide
CS-4730
n-ethyl-o-crotonotoluidine
n-ethyl-n-(2-methylphenyl)-2-butenamide #
component of eurax (salt/mix)
n-ethyl-ortho-crotonotoluidide
Q-200893
unii-2eeh27851y
crotamiton, british pharmacopoeia (bp) reference standard
HY-B1177
AB00513973_10
mfcd00026989
crotamiton, european pharmacopoeia (ep) reference standard
SR-01000759366-6
SR-01000759366-4
sr-01000759366
crotamiton, united states pharmacopeia (usp) reference standard
gtpl11165
SBI-0206763.P001
HMS3714P04
(e)-n-ethyl-n-o-tolylbut-2-enamide
Q2439845
(e)-crotamiton
AS-11641
BCP13315
n-ethyl-o-crotonotoluidide; crotamitone; crotalgin; eurasil; euraxil
BRD-K57179821-001-08-9
D70888
EN300-23049066
DTXSID101256463
(2e)-n-ethyl-n-(2-methylphenyl)-2-butenamide
HMS3393E10
crotan
DB00265
KBIOGR_001728
KBIO3_001942
NCIOPEN2_004405
SPBIO_001660
SPECTRUM2_001700
PRESTWICK0_000951
SPBIO_003091
PRESTWICK1_000951
SPECTRUM4_001234
SPECTRUM3_001081
n-ethylcrotono-o-toluidide
n-ethyl-n-(2-methylphenyl)but-2-enamide
CHEBI:31439 ,
FT-0665225
NCGC00248176-01
dtxcid4020664
dtxsid6040664 ,
crotaglin
d6s4o4xd0h ,
FT-0603174
NCGC00094571-07
HMS3369O11
CHEMBL3183440
AKOS028108434
crotamiton (ep impurity)
crotamiton (mart.)
crotamiton (usp impurity)
crotamiton (ep monograph)
crotamiton (usp monograph)
crotamiton; n-ethyl-n-(2-methylphenyl)but-2-enamide

Role	Description
antipruritic drug	A drug, usually applied topically, that relieves pruritus (itching).
scabicide	An acaricide that kills mites of the genus Sarcoptes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
enamide	An alpha,beta-unsaturated carboxylic acid amide of general formula R(1)R(2)C=CR(3)-C(=O)NR(4)R(5) in which the amide C=O function is conjugated to a C=C double bond at the alpha,beta position.
tertiary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	3.3491	0.0060	38.0041	19,952.5996	AID1159521
AR protein	Homo sapiens (human)	Potency	12.8777	0.0002	21.2231	8,912.5098	AID743035; AID743042
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	39.8686	0.0010	22.6508	76.6163	AID1224838; AID1224839
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	17.3768	0.0123	7.9835	43.2770	AID1645841
pregnane X nuclear receptor	Homo sapiens (human)	Potency	10.0000	0.0054	28.0263	1,258.9301	AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	8.1098	0.0002	29.3054	16,493.5996	AID743069
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	68.5896	0.0016	28.0151	77.1139	AID1259385
geminin	Homo sapiens (human)	Potency	0.3981	0.0046	11.3741	33.4983	AID624297
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	3.1623	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
EWS/FLI fusion protein	Homo sapiens (human)	Potency	29.6831	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	109.5000	0.1100	7.1903	10.0000	AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay ID	Title	Year	Journal	Article
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	39 (32.50)	18.7374
1990's	18 (15.00)	18.2507
2000's	18 (15.00)	29.6817
2010's	35 (29.17)	24.3611
2020's	10 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	12 (9.60%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	16 (12.80%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	25 (20.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	72 (57.60%)	84.16%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Percutaneous absorption of crotamiton in man following single and multiple dosing. Cutaneous and ocular toxicology, Volume: 25, Issue: 3	2006
[Difficulties in the treatment of scabies in infants]. Archives francaises de pediatrie, Volume: 39, Issue: 10	1982
Supercritical fluid chromatography in the routine stability control of antipruritic preparations. Journal of chromatography, Aug-16, Volume: 553, Issue: 1-2	1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

crotamiton

Cross-References

Synonyms (152)

Roles (2)

Drug Classes (2)

Protein Targets (28)

Potency Measurements

Inhibition Measurements

Biological Processes (22)

Molecular Functions (8)

Ceullar Components (13)

Bioassays (81)

Research

Studies (120)

Study Types

Research Highlights

Safety/Toxicity (1)

Bioavailability (3)

Dosage (3)

Condition	Relationship Strength	Studies	Trials
Acariasis	medium	10	2
Acne Rosacea	medium	6	1
Acquired Immune Deficiency Syndrome	low	2	0
Acquired Immuno-Deficiency Syndrome	low	2	0
Acquired Immunodeficiency Syndrome	low	2	0
Acute Liver Injury, Drug-Induced	low	1	0
AIDS	low	2	0
Allergic Contact Dermatitis	low	6	0
Anemia, Fanconi	low	1	0
Anus Diseases	low	2	0
Arthritis, Rheumatoid	low	1	0
Autosomal Dominant Hereditary Spastic Paraplegia	low	1	0
Autosomal Dominant Spastic Paraplegia Hereditary	low	1	0
Autosomal Recessive Hereditary Spastic Paraplegia	low	1	0
Autosomal Recessive Spastic Paraplegia, Hereditary	low	1	0
Benign Neoplasms	low	1	0
Blood Clot	low	1	0
Breast Cancer	low	1	0
Breast Carcinoma	low	1	0
Breast Neoplasms	low	1	0
Breast Tumors	low	1	0
Bullous Dermatoses	low	1	0
Bullous Skin Diseases	low	1	0
Cancer	low	1	0
Cancer of Breast	low	1	0
Cancer of the Breast	low	1	0
Charcot-Marie-Tooth Disease with Pyramidal Features, Autosomal Dominant	low	1	0
Chemical and Drug Induced Liver Injury	low	1	0
Chemically-Induced Liver Toxicity	low	1	0
CMT with Pyramidal Features	low	1	0
Co-infection	low	1	0
Coinfection	low	1	0
Communicable Diseases	low	1	0
Congenital Zika Syndrome	low	1	0
Congenital Zika Virus Infection	low	1	0
Cross Infection	low	2	0
Deficiency, Mental	low	1	0
Dermatitis	low	1	0
Dermatitis Medicamentosa	low	6	0
Dermatitis, Adverse Drug Reaction	low	6	0
Dermatitis, Allergic Contact	low	6	0
Dermatitis, Allergic Eczematous	low	6	0
Dermatitis, Contact, Allergic	low	6	0
Dermatitis, Periocular	low	1	0
Dermatitis, Perioral	low	1	0
Dermatoses	low	7	0
Dermatosis	low	7	0
Disability, Intellectual	low	1	0
Disease	low	2	0
Disease Models, Animal	low	2	0
Drug Eruptions	low	6	0
Drug Overdose	low	1	0
Drug-Induced Acute Liver Injury	low	1	0
Drug-Induced Liver Disease	low	1	0
Drug-Induced Liver Injury	low	1	0
Ear Diseases	low	1	0
Encephalitis, Polio	low	1	0
Epidemic Acute Poliomyelitis	low	1	0
Erythematotelangiectatic Rosacea	medium	6	1
Fanconi Anemia	low	1	0
Fanconi Hypoplastic Anemia	low	1	0
Fanconi Pancytopenia	low	1	0
Fanconi Panmyelopathy	low	1	0
Fanconi's Anemia	low	1	0
Fever, Zika	low	1	0
Folliculitis	low	1	0
Genetic Diseases, X-Chromosome Linked	low	1	0
Genetic Diseases, X-Linked	low	1	0
Genital Diseases, Male	low	1	0
Granulomatous Rosacea	medium	6	1
Hansen Disease	low	1	0
Hansen's Disease	low	1	0
Health Care Associated Infection	low	2	0
Health Care Associated Infections	low	2	0
Healthcare Associated Infections	low	2	0
Hepatitis, Drug-Induced	low	1	0
Hepatitis, Toxic	low	1	0
Hereditary Autosomal Dominant Spastic Paraplegia	low	1	0
Hereditary Autosomal Recessive Spastic Paraplegia	low	1	0
Hereditary Motor and Sensory Neuropathy 5	low	1	0
Hereditary Motor And Sensory Neuropathy V	low	1	0
Hereditary Motor-Sensory Neuropathy with Pyramidal Signs	low	1	0
Hereditary Spastic Paraplegia	low	1	0
Hereditary Spastic Paraplegia, Autosomal Recessive	low	1	0
Hereditary X-Linked Recessive Spastic Paraplegia	low	1	0
Hereditary, Spastic Paraplegia, Autosomal Dominant	low	1	0
Hereditary, Spastic Paraplegia, X-Linked Recessive	low	1	0
Hives	low	1	0
HMSN 5	low	1	0
HMSN Type V	low	1	0
HMSN V	low	1	0
HMSN V (Hereditary Motor and Sensory Neuropathy Type V)	low	1	0
Hospital Infections	low	2	0
Human Mammary Carcinoma	low	1	0
Hyperplasia	low	1	0
Hypertrophic Motor-Sensory Neuropathy-Spastic Paraplegia	low	1	0
Idiocy	low	1	0
Immunodeficiency Syndrome, Acquired	low	2	0
Immunologic Deficiency Syndrome, Acquired	low	2	0
Infantile Paralysis	low	1	0
Infection, Cross	low	2	0
Infections, Hospital	low	2	0
Infections, Nosocomial	low	2	0
Infectious Diseases	low	1	0
Inflammation	low	1	0
Innate Inflammatory Response	low	1	0
Insect Bites	medium	1	1
Insect Bites and Stings	medium	1	1
Insect Stings	medium	1	1
Intellectual Development Disorder	low	1	0
Intellectual Disability	low	1	0
Itching	medium	19	1
Leg Dermatoses	low	2	0
Leg Dermatosis	low	2	0
Leprosy	low	1	0
Lice Infestations	low	5	0
Liver Injury, Drug-Induced	low	1	0
Liver Injury, Drug-Induced, Acute	low	1	0
Maculopapular Drug Eruption	low	6	0
Maculopapular Exanthem	low	6	0
Male Genital Diseases	low	1	0
Malignancy	low	1	0
Malignant Neoplasm of Breast	low	1	0
Malignant Neoplasms	low	1	0
Malignant Tumor of Breast	low	1	0
Mammary Cancer	low	1	0
Mammary Carcinoma, Human	low	1	0
Mammary Neoplasm, Human	low	1	0
Mammary Neoplasms, Human	low	1	0
Mange	medium	10	2
Mange, Sarcoptic	medium	50	6
Mental Deficiency	low	1	0
Mental Retardation	low	1	0
Mental Retardation, Psychosocial	low	1	0
Mite Infestations	medium	10	2
Mixed Infection	low	1	0
Morbilliform Drug Reaction	low	6	0
Morbilliform Exanthem	low	6	0
Nail Diseases	low	1	0
Necrosis	low	1	0
Neoplasia	low	1	0
Neoplasm	low	1	0
Neoplasms	low	1	0
Neoplasms, Benign	low	1	0
Neoplasms, Breast	low	1	0
Nosocomial Infections	low	2	0
Ocular Rosacea	medium	6	1
Otologic Diseases	low	1	0
Otological Diseases	low	1	0
Papulopustular Rosacea	medium	6	1
Paraplegia, Spastic, Hereditary	low	1	0
Parasitic Skin Diseases	low	1	0
Pediculosis	low	5	0
Pemphigoid	low	1	0
Pemphigoid, Bullous	low	1	0
Periocular Dermatitis	low	1	0
Perioral Dermatitis	low	1	0
Peroneal Muscular Atrophy with Pyramidal Features, Autosomal Dominant	low	1	0
Phymatous Rosacea	medium	6	1
Polio	low	1	0
Polio Encephalitis	low	1	0
Poliomyelitis	low	1	0
Poliomyelitis Infection	low	1	0
Poliomyelitis, Acute	low	1	0
Poliomyelitis, Nonpoliovirus	low	1	0
Poliomyelitis, Preparalytic	low	1	0
Polymicrobial Infection	low	1	0
Pregnancy	low	2	0
Pruritis	medium	19	1
Pruritus	medium	19	1
Pustular Dermatosis, Subcorneal	low	1	0
Retardation, Mental	low	1	0
Rheumatoid Arthritis	low	1	0
Rosacea	medium	6	1
Secondary Infection	low	1	0
Secondary Infections	low	1	0
Skin and Subcutaneous Tissue Disorders	low	7	0
Skin Diseases	low	7	0
Skin Diseases, Bullous	low	1	0
Skin Diseases, Parasitic	low	1	0
Skin Diseases, Vesicular	low	1	0
Skin Diseases, Vesiculobullous	low	1	0
Sneddon-Wilkinson Disease	low	1	0
Spastic Paraplegia 2	low	1	0
Spastic Paraplegia Type 2	low	1	0
Spastic Paraplegia-Hypertrophic Motor-Sensory Neuropathy	low	1	0
Spastic Paraplegia, Autosomal Dominant, Hereditary	low	1	0
Spastic Paraplegia, Autosomal Recessive, Hereditary	low	1	0
Spastic Paraplegia, Hereditary	low	1	0
Spastic Paraplegia, Hereditary, Autosomal Dominant	low	1	0
Spastic Paraplegia, Hereditary, Autosomal Recessive	low	1	0
Spastic Paraplegia, Hereditary, X-Linked Recessive	low	1	0
Spastic Paraplegia, X-Linked Recessive, Hereditary	low	1	0
Subcorneal Pustular Dermatosis	low	1	0
Sycosis	low	1	0
Thrombosis	low	1	0
Thrombus	low	1	0
Toxic Hepatitis	low	1	0
Tumors	low	1	0
Tumors, Breast	low	1	0
Type V Hereditary Motor and Sensory Neuropathy	low	1	0
Urticaria	low	1	0
Vesicular Skin Diseases	low	1	0
Vesiculobullous Dermatoses	low	1	0
Vesiculobullous Skin Diseases	low	1	0
Vulvar Diseases	low	3	0
X Linked Recessive Hereditary Spastic Paraplegia	low	1	0
X-Linked Genetic Diseases	low	1	0
X-linked Recessive Hereditary Spastic Paraplegia	low	1	0
X-Linked, Spastic Paraplegia, Hereditary	low	1	0
Zika Fever	low	1	0
Zika Virus Disease	low	1	0
Zika Virus Infection	low	1	0
ZikV Infection	low	1	0
Congenital Zika Syndrome	low	1	0
Congenital Zika Virus Infection	low	1	0
Disease Models, Animal	low	1	0
Fever, Zika	low	1	0
Zika Fever	low	1	0
Zika Virus Disease	low	1	0
Zika Virus Infection	low	1	0
ZikV Infection	low	1	0

Article	Year
Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology, Volume: 80, Issue: 5	2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Crotamiton-loaded tea tree oil containing phospholipid-based microemulsion hydrogel for scabies treatment: Drug delivery, Volume: 28, Issue: 1	2021
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46	2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

crotamiton

Cross-References

Synonyms (152)

Roles (2)

Drug Classes (2)

Protein Targets (28)

Potency Measurements

Inhibition Measurements

Biological Processes (22)

Molecular Functions (8)

Ceullar Components (13)

Bioassays (81)

Research

Studies (120)

Study Types

Related Drugs (617)

Related Conditions (215)

Research Highlights

Safety/Toxicity (1)

Bioavailability (3)

Dosage (3)